eISSN 2508-3589
pISSN 2508-1926

Table. 4.

Table. 4.

Review of treat-and-extend regimens of intravitreal aflibercept injection in exudative age-related macular degeneration at 1 year

Study N Mean BCVA gain Mean CMT change (μm) Mean injections ≥ 12 weeks injection interval (%)
Ohji et al. [20] (2020) 123 (IVT-AFL-2W) 9.0 letters (ETDRS) -130 7.2 42.3
123 (IVT-AFL-4W) 8.4 letters (ETDRS) -126 6.9 49.6
Gillies et al. [21] (2019) 281 4.9 letters (ETDRS) 9.7 16.0
Haga et al. [7] (2018) 41 -0.32 logMAR -161 7.5
Decroos et al. [10] (2017) 31 7.2 letters (ETDRS) -143 8.0 35.0
Yamamoto et al. [22] (2017) 67 -0.15 logMAR -194 8.3 17.9
Our study 36 -0.18 logMAR -136 6.8 52.8

BCVA = best-corrected visual acuity; CMT = central macular thickness; IVT-AFL = intravitreal aflibercept; 2W = 2 weeks adjustment; ETDRS = early treatment diabetic retinopathy study letter score; 4W = 4 weeks adjustment; log MAR = logarithm of the minimal angle of resolution.

J Retin 2021;6:99-109 https://doi.org/10.21561/jor.2021.6.2.99
© 2021 J Retin